Iovance Biotherapeutics is trading 4.62% down at $14.04, with the move consistent with broader biotech-sector weakness.
- No credible company-specific announcement explaining the October 16, 2026 decline surfaced in the search.
- XBI was down 2.06% in the market context.
- Broader biotech coverage cited cautious investors and rising-interest-rate concerns, but did not identify a specific catalyst for this morning’s move.